Document Detail


Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.
MedLine Citation:
PMID:  11481696     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopa-therapy. Preclinical data in the 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) monkey suggest that alpha-2 antagonists may reduce dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. We assessed, in a pilot randomised placebo-controlled study, the effects of single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan, an alpha-2 antagonist, on motor parkinsonian disability and L-DOPA-induced dyskinesia following an acute oral challenge of L-DOPA in 18 patients with Parkinson's disease. The severity of L-DOPA-induced dyskinesia improved after 20 mg idazoxan pretreatment, while there was no concommittant deterioration in the antiparkinsonian response to L-DOPA. These results suggest that blocking alpha-2 receptors in patients with Parkinson's disease might improve L-DOPA-induced dyskinesia without the cost of a return of parkinsonian symptomatology. Further studies are required to assess whether this property could have potential therapeutic applications in the long-term management of dyskinetic patients with Parkinson's disease.
Authors:
O Rascol; I Arnulf; H Peyro-Saint Paul; C Brefel-Courbon; M Vidailhet; C Thalamas; A M Bonnet; S Descombes; B Bejjani; N Fabre; J L Montastruc; Y Agid
Related Documents :
15927256 - Pathological synaptic plasticity in the striatum: implications for parkinson's disease.
11898536 - Parkinson's disease: surgical options.
18660736 - Early diagnosis of parkinson's disease and initiation of treatment.
14552886 - Increased striatal pre-proenkephalin b expression is associated with dyskinesia in park...
10380386 - Persistence of self in advanced alzheimer's disease.
21476446 - Does mosquito control have an effect on mosquito-borne disease? the case of ross river ...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Movement disorders : official journal of the Movement Disorder Society     Volume:  16     ISSN:  0885-3185     ISO Abbreviation:  Mov. Disord.     Publication Date:  2001 Jul 
Date Detail:
Created Date:  2001-08-01     Completed Date:  2001-10-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8610688     Medline TA:  Mov Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  708-13     Citation Subset:  IM    
Copyright Information:
Copyright 2001 Movement Disorder Society.
Affiliation:
Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France. rascol@cict.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adrenergic alpha-Antagonists / adverse effects,  therapeutic use*
Aged
Antiparkinson Agents / adverse effects*,  therapeutic use
Dose-Response Relationship, Drug
Dyskinesia, Drug-Induced / drug therapy*
Female
Humans
Idazoxan / adverse effects,  therapeutic use*
Levodopa / adverse effects*,  therapeutic use
Male
Middle Aged
Neurologic Examination / drug effects
Parkinson Disease / drug therapy*
Pilot Projects
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Antiparkinson Agents; 0/Levodopa; 79944-58-4/Idazoxan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genetic polymorphisms of superoxide dismutase in Parkinson's disease.
Next Document:  Cervical dystonia in monozygotic twins: case report and review of the literature.